Sofinnova Partners

Latent Labs is making biology programmable to transform health and sustainability for the benefit of all. We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizing existing enzymes, and advancing genetic engineering. Contact us to work with us today.

Genespire is a biotechnology company dedicated to advancing gene therapies for individuals suffering from genetic disorders, with a specific emphasis on primary immunodeficiencies and inherited metabolic diseases. The company specializes in developing innovative therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for the precise and effective insertion of therapeutic genes into blood cells, providing patients with a range of tailored treatment options suitable for their unique conditions. Genespire's mission is to transform the lives of patients affected by severe genetic diseases through cutting-edge therapeutic solutions.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

May Health specializes in developing innovative solutions for infertility related to Polycystic Ovary Syndrome (PCOS). The company offers a minimally invasive procedure aimed at restoring ovulation in women with PCOS, providing a more natural approach to pregnancy. This one-time treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure is designed to assist the body's natural ovulation process and can be conducted in a clinical setting, similar to techniques used by fertility specialists in in vitro fertilization (IVF). May Health's focus is on delivering effective, durable solutions for patients seeking to conceive while minimizing the medicalization of the pregnancy experience.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

BrightHeart is a medical technology startup that is developing artificial intelligence software to help diagnose congenital heart abnormalities in foetuses.

Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.

deepc GmbH, based in Munich, Germany, specializes in developing AI software for medical imaging, particularly in radiology, to minimize diagnostic errors. The company offers a disease-agnostic AI solution that analyzes medical imaging data in real-time, identifying healthy and non-healthy cases to enhance diagnostic accuracy. Its web-based AI software framework, referred to as the Diagnostics OS, facilitates the integration of various medical diagnostic AI tools into clinical workflows, improving efficiency and cost-effectiveness. By serving as a central hub for artificial intelligence applications in radiology, deepc aims to support healthcare professionals in achieving faster, more accurate diagnoses, ultimately leading to better patient outcomes. The company has received recognition for its innovative contributions, including awards from the Federal Ministry for Economic Affairs and Energy.

Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.

LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

Leucid Bio is a biotechnology company focused on developing innovative cell therapies for patients with refractory cancers, particularly solid tumors. Founded to leverage two decades of research from King's College London in the CAR-T field, Leucid Bio is guided by a seasoned management team possessing both scientific and commercial expertise. The company has a strong partnership with King's College, granting it exclusive access to a wealth of scientific, clinical, and manufacturing resources, particularly from Dr. Maher and his team of immuno-oncology specialists. By specializing in advanced CAR T-cell therapies, Leucid Bio aims to enhance treatment outcomes and provide durable responses for patients who have limited or no treatment options available.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

CorVent Medical specializes in the development, manufacturing, and marketing of ventilation and respiratory products aimed at addressing acute, sub-acute, and home care needs. The company has created the RESPOND ventilation platform, a compact and lightweight ventilator designed for quick deployment in various clinical settings and stockpiles. Weighing only 15 pounds, the RESPOND ventilator meets the ICU primary ventilation standard and is engineered for maintenance-free operation with a long shelf life, ensuring reliability and low total ownership costs. By utilizing advanced technologies, CorVent Medical provides healthcare providers with cost-effective solutions to manage respiratory insufficiency, allowing them to efficiently focus on critical patient care.

Genespire is a biotechnology company dedicated to advancing gene therapies for individuals suffering from genetic disorders, with a specific emphasis on primary immunodeficiencies and inherited metabolic diseases. The company specializes in developing innovative therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for the precise and effective insertion of therapeutic genes into blood cells, providing patients with a range of tailored treatment options suitable for their unique conditions. Genespire's mission is to transform the lives of patients affected by severe genetic diseases through cutting-edge therapeutic solutions.

Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes several seconds, is intended to increase the valve effective orifice area without the need to replace the valve.

May Health specializes in developing innovative solutions for infertility related to Polycystic Ovary Syndrome (PCOS). The company offers a minimally invasive procedure aimed at restoring ovulation in women with PCOS, providing a more natural approach to pregnancy. This one-time treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure is designed to assist the body's natural ovulation process and can be conducted in a clinical setting, similar to techniques used by fertility specialists in in vitro fertilization (IVF). May Health's focus is on delivering effective, durable solutions for patients seeking to conceive while minimizing the medicalization of the pregnancy experience.

HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating patients with mitral valve regurgitation. Co-founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve that can be implanted in a beating heart while preserving the native valve structure and surrounding anatomy. The innovative system allows for delivery through a transseptal passage via the femoral vein, enabling a reversible procedure that minimizes patient trauma during complex heart surgeries. HighLife's focus is on ensuring ease and safety of use, contributing to improved treatment outcomes for patients. The company's technology is currently undergoing clinical evaluation.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

EryDel, based in Urbino, has developed a patented technology for drug delivery using red blood cells (erythrocytes). This innovative approach allows for the efficient loading of various therapeutic agents, including drugs and proteins, into red blood cells, enabling their gradual release within the patient's body. This method enhances treatment efficacy while minimizing side effects, particularly beneficial for chronic conditions that typically require daily medication. EryDel's solution has been tested in patients with Inflammatory Bowel Diseases such as ulcerative colitis and Crohn's disease. The company offers comprehensive support for the drug delivery process, including a specialized device called the "Red Cell Loader" and disposable kits. Additionally, EryDel is focused on automating blood processing at the point of care, leveraging the unique properties of erythrocytes to facilitate the treatment of various rare diseases.

LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

MD Start is an incubator and fund dedicated to medical technologies. MD Start creates, develops, and operates medical projects, turning them into new companies with both strategic and hands-on approaches, in order to bring them to investment stage and commercial development.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

ReCor Medical has developed a unique therapeutic non-focused ultrasound system for performing renal denervation in patients with resistant hypertension. The PARADISE® technology (Percutaneous Renal Denervation System) includes a 6 French catheter with a cylindrical transducer that emits ultrasound energy circumferentially, allowing for a more efficient renal denervation procedure.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Entourage Medical Technologies is a biotech developing left ventricular access and closure devices for structural heart intervention.

Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company offers ZILRETTA, an intra-articular injection designed to manage knee pain associated with osteoarthritis in the United States. Additionally, Flexion is developing FX201, a gene therapy aimed at stimulating the production of an anti-inflammatory protein to provide pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Founded in 2007, Flexion Therapeutics collaborates with pharmaceutical and biotechnology companies to advance its drug candidates through clinical proof of concept and beyond, thereby enhancing their partners' portfolios while sharing expertise and risk.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company offers ZILRETTA, an intra-articular injection designed to manage knee pain associated with osteoarthritis in the United States. Additionally, Flexion is developing FX201, a gene therapy aimed at stimulating the production of an anti-inflammatory protein to provide pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Founded in 2007, Flexion Therapeutics collaborates with pharmaceutical and biotechnology companies to advance its drug candidates through clinical proof of concept and beyond, thereby enhancing their partners' portfolios while sharing expertise and risk.

Stentys S.A. is a medical device company focused on designing, developing, and marketing self-expanding stents for the treatment of cardiovascular diseases, particularly in cases of acute myocardial infarction and other complex coronary conditions. The company offers a range of products, including xpositions, mistent, stentys btk, stentys ac, and stentys stent. Stentys operates in various regions, including Europe, the Middle East, Asia, and Latin America, aiming to provide innovative solutions to enhance patient outcomes in cardiovascular care.

Stentys S.A. is a medical device company focused on designing, developing, and marketing self-expanding stents for the treatment of cardiovascular diseases, particularly in cases of acute myocardial infarction and other complex coronary conditions. The company offers a range of products, including xpositions, mistent, stentys btk, stentys ac, and stentys stent. Stentys operates in various regions, including Europe, the Middle East, Asia, and Latin America, aiming to provide innovative solutions to enhance patient outcomes in cardiovascular care.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers. We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers. Oxxius is headquartered in western France and located among a major optics and photonics cluster. Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared. Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers. We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers. Oxxius is headquartered in western France and located among a major optics and photonics cluster. Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared. Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.

BioSpace, Inc. operates an online platform dedicated to life science professionals, offering a comprehensive community for industry news and career opportunities. Through its website, BioSpace.com, the company provides a job board, daily biotech news updates, and features that facilitate connections between recruiters, job seekers, and industry professionals. This platform enhances communication and collaboration among leaders in biotechnology, pharmaceuticals, medical devices, diagnostics, clinical research, academia, and biomedical fields. Additionally, BioSpace organizes career events aimed at life science recruiting professionals in the United States and Canada. Based in Englewood, Colorado, with an office in San Francisco, BioSpace serves as a vital resource for advancing health and quality of life globally by linking innovative organizations with skilled professionals.